Corvus Pharmaceuticals CRVS Gain Loss On Sale Of Property Plant Equipment

Gain Loss On Sale Of Property Plant Equipment at other companies

Lumentum Holdings Inc.LITE

$0-100%

CRHCRH

$22M+57.1%

CytokineticsCYTK

$0+100%

Target HospitalityTH

$75K0.0%

Digital RealtyDLR

$42.87M-70.4%

HBT

HBT Financial, Inc.HBT

$0-100%

Other financials

Income statement

See full

Operating income-$14.9M-49.9%

Net income-$13.7M-190%

EPS (diluted)-$0.15-15.4%

Balance sheet

See full

Cash & equivalents$40.1M+702%

Total debt$834.0K-27.7%

Total equity$240.7M+388%

Total assets$253.2M+326%

Cash flow

See full

Operating cash flow-$10.4M-25.5%

CapEx$91.0K+153%

Free cash flow-$10.5M-26.1%

Valuation

See full

Market cap$1.1B+259%

Enterprise value$1.06B+251%

Returns & leverage

See full

Return on equity-30.5%-12.5pp

Debt / equity0×0.0×

Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: Corvus Pharmaceuticals’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corvus Pharmaceuticals's gain loss on sale of property plant equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Corvus Pharmaceuticals's gain loss on sale of property plant equipment?: Corvus Pharmaceuticals (CRVS) reported gain loss on sale of property plant equipment of $1.25K in Q4 2024.